Inflammatory markers in cystic fibrosis (Q40751351)

23 September 2017

Inflammatory markers in cystic fibrosis (English)

1 reference

23 September 2017

0 references

Rayner RJ

1

1 reference

23 September 2017

Wiseman MS

2

1 reference

23 September 2017

Cordon SM

3

1 reference

23 September 2017

Norman D

4

1 reference

23 September 2017

Hiller EJ

5

1 reference

23 September 2017

Shale DJ

6

1 reference

23 September 2017

1 March 1991

1 reference

23 September 2017

1 reference

23 September 2017

85

1 reference

23 September 2017

2

1 reference

23 September 2017

139-145

1 reference

What is a "pulmonary exacerbation" in cystic fibrosis?

23 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2806%2980292-1

7 January 2021

Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2806%2980292-1

7 January 2021

Elastase-alpha 1-proteinase inhibitor: an early indicator of septicemia and bacterial meningitis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2806%2980292-1

7 January 2021

Granulocyte elastase-alpha 1-antiproteinase complex in cystic fibrosis: sensitive plasma assay for monitoring pulmonary infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2806%2980292-1

7 January 2021

Neutrophil degranulation and increased pulmonary capillary permeability following oesophagectomy: a model of early lung injury in man

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2806%2980292-1

7 January 2021

Diagnostic criteria for adult respiratory distress syndrome: time for reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2806%2980292-1

7 January 2021

Serum C-reactive protein in assessment of pulmonary exacerbations and antimicrobial therapy in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2806%2980292-1

7 January 2021

Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2806%2980292-1

7 January 2021

The systematic evaluation of the chest radiograph in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2806%2980292-1

7 January 2021

A rapid and sensitive solid-phase enzyme immunoassay for C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2806%2980292-1

7 January 2021

Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2806%2980292-1

7 January 2021

Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2806%2980292-1

7 January 2021

Monitoring the acute phase response

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2806%2980292-1

7 January 2021

Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2806%2980292-1

7 January 2021

Levels of free granulocyte elastase in bronchial secretions from patients with cystic fibrosis: effect of antimicrobial treatment against Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2806%2980292-1

7 January 2021

10.1016/S0954-6111(06)80292-1

Identifiers

DOI

1 reference

23 September 2017

1 reference